

Hironori Tanaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9437135/publications.pdf>

Version: 2024-02-01

19
papers

317
citations

840119

11
h-index

887659

17
g-index

20
all docs

20
docs citations

20
times ranked

535
citing authors

#	ARTICLE	IF	CITATIONS
1	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 277-285.	0.9	66
2	MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 7207-7215.	0.8	52
3	Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overloc</i>	0.4	36
4	Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecularly-targeted agent sequential therapy: A propensity score-matched analysis. <i>Hepatology Research</i> , 2021, 51, 472-481.	1.8	23
5	Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and <i>in vitro</i> assessment via protein phosphorylation array. <i>Oncotarget</i> , 2020, 11, 2531-2542.	0.8	20
6	Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2010, 30, 1027-1032.	1.9	18
7	MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4917.	1.7	17
8	Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome. <i>Liver International</i> , 2015, 35, 1707-1714.	1.9	15
9	Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 1135-1139.	0.7	14
10	APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism. <i>BMC Gastroenterology</i> , 2018, 18, 24.	0.8	13
11	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 1275-1283.	0.7	12
12	Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome. <i>PLoS ONE</i> , 2020, 15, e0238388.	1.1	9
13	Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome. <i>BMC Gastroenterology</i> , 2016, 16, 17.	0.8	8
14	Effects of audio and visual distraction on patients' vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial. <i>BMC Gastroenterology</i> , 2020, 20, 122.	0.8	4
15	An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration. <i>Internal Medicine</i> , 2021, 60, 1839-1845.	0.3	4
16	Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2020, 55, 1072-1086.	2.3	3
17	Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma. <i>Digestion</i> , 2017, 95, 242-251.	1.2	2
18	Hepatocellular carcinoma producing granulocyte-colony stimulating factor accompanied with peritonitis carcinomatosa. <i>Acta Hepatologica Japonica</i> , 2015, 56, 518-525.	0.0	1

#	ARTICLE	IF	CITATIONS
19	Development of a renal subcapsular hematoma during angiography for diagnosis and subsequent treatment of hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2014, 7, 185-188.	0.4	0